Abstract
Down's syndrome is an autosomal disease and its prenatal screening is particularly important.In recent years, clinical application of serological screening markers has been widely used,which improved the detection rate of Down's syndrome,but still remained at about 60%.The new generation of sequencing technology for direct analysis of nucleic acids, which can be used for fetal chromosomal aneuploidy detection,can detect Down's syndrome more accurately.In this paper,we compared the prenatal screening methods for Down's syndrome in recent decades,and reviewed the new screening markers based on proteomics and bioinformatics technology for clinical application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Academic Journal of Second Military Medical University
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
